shigenori ota

Dr. shigenori ota

Department of Surgery, Surgical Oncology and Science, Sapporo Medical University
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MIMasafumi Imamura
Masafumi Imamura
MNMinoru Nagayama
Minoru Nagayama
Daisuke KyunoDaisuke Kyuno
Daisuke Kyuno
SOshigenori ota
shigenori ota
TMTakeshi Murakami
Takeshi Murakami
ITIchiro Takemasa
Ichiro Takemasa
We aimed to identify the perioperative predictors of the early recurrence (ER) of resectable and borderline-resectable pancreatic ductal adenocarcinomas (PDACs). After surgery for a PDAC, most patients develop a recurrence. Predictive factors may therefore guide therapeutic decision-making. Patients (n = 234) who underwent a pancreatectomy for a PDAC between 2006 and 2019 were included. The postrecurrence survival (PRS) was estimated using Kaplan–Meier curves. Predictive factors for an ER were assessed using logistic regression analyses; 93 patients (39.7%) were recurrence-free at the last follow-up. Patients with an ER (n = 85, 36.3%), defined as a recurrence within the first 12 months after surgery, had 1- and 2-year PRS rates of 38.7% and 9.5%, respectively, compared with 66.9% and 37.2% for those with a late recurrence (n = 56, 23.9%; both p < 0.001). The most common site of an ER was the liver (55.3%) with a significantly shorter median overall survival time than that with either a local or a lung recurrence (14.5 months; p < 0.001). Preoperative and postoperative risk factors for an ER included a tumor size >3.0 cm (odds ratio (OR): 3.11, 95% confidence interval (CI): 1.35–7.14) and preoperative carbohydrate antigen 19-9 (CA19-9) levels >52 U/mL (OR: 3.25, 95% CI: 1.67–6.30) and a pathological tumor size >3.0 cm (OR: 2.00, 95% CI: 1.03–3.90) and postoperative carbohydrate antigen 19-9 levels >37 U/mL (OR: 2.11, 95% CI: 1.02–4.36), respectively. Preoperatively (>52 U/mL) and postoperatively (>37 U/mL) elevated CA19-9 and a tumor size >3.0 cm were independent predictors for an ER after a pancreatectomy for a PDAC.

19 May 2021 in Pancreas
Verified
Journal Article
Open access
MSMasahiro Shitani
Masahiro Shitani
JOJiro Ogino
Jiro Ogino
MIMai Isosaka
Mai Isosaka
MIMiki Ito
Miki Ito
HFHiroki Fujino
Hiroki Fujino
Hiroshi NakaseHiroshi Nakase
Hiroshi Nakase
An abstract is unavailable. This article is available as a PDF only.

28 February 2021 in World Journal of Meta-Analysis
Verified
Journal Article
Open access
TITomohiro Ishinuki
Tomohiro Ishinuki
SOshigenori ota
shigenori ota
KHKohei Harada
Kohei Harada
HTHiroomi Tatsumi
Hiroomi Tatsumi
KHKeisuke Harada
Keisuke Harada
TMToru Mizuguchi
Toru Mizuguchi
Mortality after hepatectomy has decreased, and the quality of various surgical approaches to hepatectomy have been evaluated. Various assessments of quality of life (QOL) after hepatectomy have been developed and investigated in different clinical settings. To conduct a systematic review and meta-analysis to examine two clinical topics: Laparoscopic hepatectomy vs open hepatectomy, and preoperative QOL status vs postoperative QOL status. A systematic literature search was performed using PubMed and MEDLINE, including the Cochrane Library Central. The following inclusion criteria were set for inclusion in this meta-analysis: (1) Studies comparing preoperative QOL and postoperative QOL; and (2) Studies comparing QOL between laparoscopic hepatectomy and open hepatectomy. A total of 8 articles were included in this meta-analysis. QOL was better after laparoscopic hepatectomy than after open hepatectomy. The outcomes of evaluations of QOL after hepatectomy can depend on the type of questionnaire used, the timing of the assessment, and the etiology of the hepatic disease.